论文部分内容阅读
目的观察厄贝沙坦对糖尿病肾病患者的有效性和安全性。方法糖尿病肾病患者65例,控制血糖和血压,随机分为治疗组和对照组,治疗组加用厄贝沙坦300mg/d,观察8周,检测两组尿白蛋白排泄率(UAER)、血尿素氮、肌肝、甘油三酯、胆固醇、糖化血红蛋白、空腹血糖等生化指标。结果厄贝沙坦300mg/d,能有效降低糖尿病肾病患者的UAER,对肾功能无明显影响,而不依赖于血压的下降,具有良好的安全性和耐受性。
Objective To observe the efficacy and safety of irbesartan in patients with diabetic nephropathy. Methods Sixty-five patients with diabetic nephropathy were randomly divided into treatment group and control group. Irbesartan 300 mg / d was given to the treatment group for 8 weeks. Urinary albumin excretion rate (UAER) and blood Urea nitrogen, muscle liver, triglycerides, cholesterol, glycosylated hemoglobin, fasting blood glucose and other biochemical indicators. The results irbesartan 300mg / d, can effectively reduce the diabetic nephropathy UAER, no significant effect on renal function, without dependence on the decline in blood pressure, with good safety and tolerability.